Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus etomidate for anesthesia induction hemodynamics in coronary heart disease patients undergoing non-cardiac surgery
ChiCTR2600134822Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis comparing Control group (etomidate group) with Experimental group (remimazolam group) (2 arms). Primary endpoint: Hypotension. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
remimazolametomidate
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2600134822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134822.